-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 6th, Hengrui Medicine issued an announcement that the “Drug Registration Certificate” for carrelizumab for injection was approved and issued by the subsidiary State Food and Drug Administration.
Carrelizumab for injection is a humanized anti-PD-1 monoclonal antibody that can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway, restore the body’s anti-tumor immunity, thereby Form the basis of cancer immunotherapy.
After querying the EvaluatePharma database, the global sales of anti-PD-1 antibodies in 2020 will be approximately US$23.